Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC

Fineline Cube Jul 14, 2026
Company Deals

GSK Terminates $2.2 Billion Neurodegenerative Disease Partnership with Alector Following Dual Clinical Failures

Fineline Cube Jul 14, 2026
Company Deals

Zhaoke Ophthalmology Acquires Global Rights to NVK002 for Myopia Control, Licenses U.S. Rights to Nevakar

Fineline Cube Jul 14, 2026
Company Deals

Sisram Medical Restructures DaxibotulinumtoxinA Partnership with Fosun Wanbang Through New Sublicense and Promotion Services Agreements

Fineline Cube Jul 13, 2026
Company Deals

Teva Secures Global Rights to Polpharma Biologics’ Ocrelizumab Biosimilar, Expanding Multiple Sclerosis Portfolio

Fineline Cube Jul 13, 2026
Policy / Regulatory

China’s National Health Commission Launches Comprehensive Continuous Medication Management Framework to Enhance Patient Safety and Healthcare Quality

Fineline Cube Jul 13, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Breakthrough Therapy Designation for HRS-7058 in KRAS G12C-Mutant Pancreatic Cancer

Fineline Cube Jul 14, 2026
Company Drug

Fosun Pharma Secures NMPA Approval for Phase 1 Trial of HLX37 Bispecific Antibody in Combination Therapies for Advanced Solid Tumors

Fineline Cube Jul 14, 2026
Company Deals

Revvity and Sanyou Biopharmaceuticals Deepen Partnership to Advance Biologic Drug Development

Fineline Cube Jun 27, 2024

Shanghai-based biotechnology company Revvity has entered into a comprehensive partnership with Sanyou Biopharmaceuticals Co., Ltd...

Company Drug

Novartis’s Scemblix STAMP Inhibitor for CML Accepted for Review by China’s NMPA

Fineline Cube Jun 27, 2024

Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has had its market filing for Scemblix (asciminib)...

Company Drug

Novo Nordisk’s Ocedurenone Misses Primary Endpoint in Chronic Kidney Disease Trial

Fineline Cube Jun 27, 2024

Novo Nordisk (NYSE: NVO; CPH: NOVO-B), a Danish pharmaceutical company, has announced that its pipeline...

Company Drug

Merck’s HER3-Targeted ADC Patritumab Deruxtecan Faces FDA Complete Response Letter

Fineline Cube Jun 27, 2024

Merck, Sharp & Dohme Inc. (NYSE: MRK), a leading U.S. pharmaceutical company, has announced that...

Company Drug

Moderna’s RSV Vaccine Efficacy Wanes to 50% After 18 Months, Shares Slide

Fineline Cube Jun 27, 2024

Moderna Inc. (NASDAQ: MRNA), a U.S.-based biopharmaceutical company, has announced long-term efficacy data for its...

Company Deals

CASI Pharmaceuticals Secures USD 15 Million in PIPE Transaction for Anti-CD38 Monoclonal Antibody Development

Fineline Cube Jun 27, 2024

CASI Pharmaceuticals (NASDAQ: CASI), a biopharmaceutical company based in China, has announced the signing of...

Company Drug

J&J Halts Mid-Stage Trial for Tremfya in Giant Cell Arteritis Due to Efficacy Concerns

Fineline Cube Jun 26, 2024

Johnson & Johnson (J&J; NYSE: JNJ), a leading U.S.-based healthcare company, has reportedly discontinued a...

Company Drug

AstraZeneca’s Tagrisso Wins NMPA Approval for First-Line EGFR-mutated NSCLC Treatment

Fineline Cube Jun 26, 2024

AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical company, has announced that it has received another...

Company Deals

Sanofi Invites Bids Starting at $20 Billion for Consumer Health Unit

Fineline Cube Jun 26, 2024

Sanofi (NYSE: SNY) is reportedly inviting bids starting at USD 20 billion for its consumer...

Policy / Regulatory

China’s NMPA Proposes Expedited Review for Clinically Urgent Overseas Drugs

Fineline Cube Jun 26, 2024

The National Medical Products Administration (NMPA) has released a draft proposal titled “Announcement of the...

Company Deals Digital R&D

Eli Lilly & Co. Partners with OpenAI to Use Generative AI in Antimicrobial Drug Discovery

Fineline Cube Jun 26, 2024

Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the U.S., has...

Company Deals

Aidea Pharmaceutical to Boost Stake in Nanda Pharmaceutical to 51.1256%

Fineline Cube Jun 26, 2024

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a pharmaceutical company based in China, is poised...

Company Drug

Sino Biopharmaceutical Gains NMPA Approval for Liraglutide Biosimilar for Type 2 Diabetes

Fineline Cube Jun 26, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a major player in China’s pharmaceutical industry, has announced that...

Company Drug

CSPC Pharmaceutical’s BCMA-Targeted CAR-T Therapy SYS6020 Receives NMPA Clinical Trial Approval

Fineline Cube Jun 26, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...

Company Drug

Novo Nordisk’s Semaglutide for Long-Term Weight Management Receives NMPA Approval

Fineline Cube Jun 26, 2024

Novo Nordisk (NYSE: NVO, CPH: NOVO-B), a leading healthcare company from Denmark, has announced that...

Company Drug

Jiangsu Simcere Pharmaceutical Wins NMPA Nod for Biosimilar Version of Erbitux

Fineline Cube Jun 26, 2024

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096), a Chinese pharmaceutical company, has announced that it...

Company Deals

Walvax Biotechnology Halts COVID-19 mRNA Vaccine Trials Co-Developed with Abogen Biosciences

Fineline Cube Jun 26, 2024

Walvax Biotechnology Co., Ltd (SHE: 300142), a biopharmaceutical company based in China, has announced the...

Company Policy / Regulatory

U.S. Lawmakers Question FDA on Discrepancies in Foreign Inspections of China and India

Fineline Cube Jun 25, 2024

U.S. lawmakers have intensified their scrutiny of the FDA’s foreign inspection program, particularly for companies...

Company

Novo Nordisk to Pump USD 4.1 Billion into U.S. Manufacturing Expansion

Fineline Cube Jun 25, 2024

Novo Nordisk (NYSE: NVO), a Danish biopharmaceutical company, has announced plans to invest USD 4.1...

Company Drug

Merck KGaA’s Xevinapant Misses Primary Endpoint in Phase III Head and Neck Cancer Trial

Fineline Cube Jun 25, 2024

Merck KGaA (NYSE: MRK), a leading German pharmaceutical company, has encountered a setback in the...

Posts pagination

1 … 368 369 370 … 694

Recent updates

  • Hengrui Pharmaceuticals Secures NMPA Breakthrough Therapy Designation for HRS-7058 in KRAS G12C-Mutant Pancreatic Cancer
  • Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC
  • GSK Terminates $2.2 Billion Neurodegenerative Disease Partnership with Alector Following Dual Clinical Failures
  • Fosun Pharma Secures NMPA Approval for Phase 1 Trial of HLX37 Bispecific Antibody in Combination Therapies for Advanced Solid Tumors
  • Zhaoke Ophthalmology Acquires Global Rights to NVK002 for Myopia Control, Licenses U.S. Rights to Nevakar
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Secures NMPA Breakthrough Therapy Designation for HRS-7058 in KRAS G12C-Mutant Pancreatic Cancer

Company Deals

Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC

Company Deals

GSK Terminates $2.2 Billion Neurodegenerative Disease Partnership with Alector Following Dual Clinical Failures

Company Drug

Fosun Pharma Secures NMPA Approval for Phase 1 Trial of HLX37 Bispecific Antibody in Combination Therapies for Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.